Efficacy and Safety of Duloxetine in Chinese Solid Tumor Patients With Taxanes-induced Painful Peripheral Neuropathy
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
The study is to evaluate the efficacy and safety of duloxetine in Chinese solid tumor
patients with taxanes-induced painful peripheral neuropathy. Duloxetine will be given to
patients who have grade 1 or higher sensory neuropathy according to the NCI Common
Terminology Criteria for Adverse Events (CTCAE) version 5.0 and at least 4 on a scale of 0 to
10 points, representing average chemotherapy-induced pain, after taxanes treatment.
Patient-reported pain severity, functional interference, emotion condition and quality of
Life will be assessed weekly using corresponding scales. Blood samples will be collected from
each enrolled subjects before the start of treatment, and the potential biomarkers in
predicting duloxetine efficacy or safety will be explored by genomic profiling.